Advertisement

Resistance to Ibritumomab in Lymphoma

  • Makoto Hosono
  • Jean-François Chatal

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 18)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Yoichi Tatsumi
    Pages 9-31
  3. Takayoshi Ishimori, Koya Nakatani
    Pages 67-77
  4. Kohei Hanaoka, Makoto Hosono
    Pages 99-104
  5. Gerhard Glatting
    Pages 105-117
  6. Jean-Baptiste Gorin, Jérémie Ménager, Yannick Guilloux, Jean-François Chatal, Joëlle Gaschet, Michel Chérel
    Pages 119-137
  7. Clément Bailly, Caroline Bodet-Milin, François Guérard, Caroline Rousseau, Michel Chérel, Françoise Kraeber-Bodéré et al.
    Pages 139-153
  8. Back Matter
    Pages 155-158

About this book

Introduction

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

Keywords

Ibritumomab Lymphoma Non-Hodgkin's Follicular B-cell Toxicity

Editors and affiliations

  • Makoto Hosono
    • 1
  • Jean-François Chatal
    • 2
  1. 1.Institute of Advanced Clinical MedicineKindai University Faculty of MedicineOsakaJapan
  2. 2.GIP ArronaxNantes-Saint-HerblainFrance

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-78238-6
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-319-78237-9
  • Online ISBN 978-3-319-78238-6
  • Series Print ISSN 2196-5501
  • Series Online ISSN 2196-551X
  • Buy this book on publisher's site
Industry Sectors
Pharma
Biotechnology
Consumer Packaged Goods